Sarepta Therapeutics (SRPT) Tops Q3 EPS by 68c
Tweet
Share
E-mail
Get Alerts SRPT Hot Sheet
Join SI Premium – FREE
Sarepta Therapeutics (NASDAQ: SRPT) reported Q3 EPS of $0.62, $0.68 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $467.2 million versus the consensus estimate of $407.73 million.
For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- NAHB housing market index rises to 35 in August from 34
- Andreessen Horowitz subject of DoJ probe - Bloomberg
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
